<?xml version="1.0"?>
<trials subjects="1">
  <Triall>
    <main>
      <UTRN />
      <trial_id>ChiCTR-INR-17014226</trial_id>
      <utrn />
      <reg_name>ChiCTR</reg_name>
      <date_registration>2017-12-30</date_registration>
      <primary_sponsor>Tianjin First Central Hospital</primary_sponsor>
      <public_title>A randomized, single blind clinical study of human umbilical cord mesenchymal stem cells compare sodium hyaluronate to treatment of early osteoarthritis of the knee</public_title>
      <acronym />
      <scientific_title>A randomized, single blind clinical study of human umbilical cord mesenchymal stem cells compare sodium hyaluronate to treatment of early osteoarthritis of the knee</scientific_title>
      <Scientific_acronym />
      <date_enrolment>2018-03-01</date_enrolment>
      <type_enrolment />
      <target_size>A:20;B:20;</target_size>
      <recruitment_status>Pending</recruitment_status>
      <url>http://www.chictr.org.cn/showproj.aspx?proj=24318</url>
      <study_type>Interventional study</study_type>
      <study_design>Randomized parallel controlled trial</study_design>
      <phase>New Treatment Measure Clinical Study</phase>
      <hc_freetext>Osteoarthritis</hc_freetext>
      <i_freetext>A:Sodium hyaluronate group;B:human Umbilical Cord -Mesenchymal Stem Cells  group;</i_freetext>
      <results_actual_enrolment />
      <results_date_completed />
      <results_url_link />
      <results_summary />
      <results_date_posted />
      <results_date_first_publication />
      <results_baseline_char />
      <results_participant_flow />
      <results_adverse_events />
      <results_outcome_measures />
      <results_url_protocol />
      <results_IPD_plan>Yes</results_IPD_plan>
      <results_IPD_description />
    </main>
    <contacts>
      <contact>
        <type>Scientific</type>
        <firstname>Pengfei Wang</firstname>
        <middlename />
        <lastname />
        <address>Department of orthopedics, Tianjin First Central Hospital, 24 Fukang Road, Nankai District, Tianjin, China</address>
        <city />
        <country1 />
        <zip />
        <telephone>+86 18622536848</telephone>
        <email>feition2417@163.com</email>
        <affiliation>Tianjin First Central Hospital</affiliation>
      </contact>
      <contact>
        <type>Public</type>
        <firstname>Wenxue Jiang</firstname>
        <middlename />
        <lastname />
        <address>Department of orthopedics, Tianjin First Central Hospital, 24 Fukang Road, Nankai District, Tianjin, China</address>
        <city />
        <country1 />
        <zip />
        <telephone>+86 13752002876</telephone>
        <email>jiangwenxue1920@163.com</email>
        <affiliation>Tianjin First Central Hospital</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>China</country2>
    </countries>
    <criteria>
      <inclusion_criteria>1. Knee osteoarthritis not more than 6 months of conservative treatment;
2. The VAS score was less than 6;
3. The knee joint activity decreased;
4. The K-L score was lower than grade 3;
5. The patient aged under 65 years;
6. Patients with primary osteoarthritis of the knee.</inclusion_criteria>
      <agemin />
      <agemax>65</agemax>
      <gender>Both</gender>
      <exclusion_criteria>1. Autoimmune arthropathy;
2. Unstable or damaged ligaments;
3. There was infection, surgery and radioactivity for the knee joint within 6 weeks;
4. The immunosuppressant was made in 6 weeks;
5. Glucocorticoids or sodium hyaluronate were injected within 3 months;
6. Pregnant or lactating women;
7. Abnormal coagulation function;
8. Infection in the skin of the injection area. 
9. The investigator cognizanced the patients unsuitable in the study.</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code />
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword />
    </health_condition_keyword>
    <intervention_code>
      <i_code>;;</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword />
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>X-ray;Nuclear Magnetic Resonance Imaging;VAS score;WOmAC score;</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome />
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name />
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id />
        <issuing_authority />
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Self financing</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Not approved</status>
        <approval_date>2013-08-26</approval_date>
        <contact_name />
        <contact_address />
        <contact_phone />
        <contact_email />
      </ethics_review>
    </ethics_reviews>
  </Triall>
</trials>